Literature DB >> 18083859

Relevant double mutations in bioengineered Streptomyces clavuligerus deacetoxycephalosporin C synthase result in higher binding specificities which improve penicillin bioconversion.

Kian Sim Goo1, Chun Song Chua, Tiow-Suan Sim.   

Abstract

Streptomyces clavuligerus deacetoxycephalosporin C synthase (ScDAOCS) is an important industrial enzyme for the production of 7-aminodeacetoxycephalosporanic acid, which is a precursor for cephalosporin synthesis. Single mutations of six amino acid residues, V275, C281, N304, I305, R306, and R307, were previously shown to result in enhanced levels of ampicillin conversion, with activities ranging from 129 to 346% of the wild-type activity. In this study, these mutations were paired to investigate their effects on enzyme catalysis. The bioassay results showed that the C-terminal mutations (N304X [where X is alanine, leucine, methionine, lysine, or arginine], I305M, R306L, and R307L) in combination with C281Y substantially increased the conversion of ampicillin; the activity was up to 491% of the wild-type activity. Similar improvements were observed for converting carbenicillin (up to 1,347% of the wild-type activity) and phenethicillin (up to 1,109% of the wild-type activity). Interestingly, the N304X R306L double mutants exhibited lower activities for penicillin G conversion, and activities that were 40 to 114% of wild-type enzyme activity were detected. Based on kinetic studies using ampicillin, it was clear that the increases in the activities of the double mutants relative to those of the corresponding single mutants were due to enhanced substrate binding affinities. These results also validated the finding that the N304R and I305M mutations are ideal for increasing the substrate binding affinity and turnover rate of the enzyme, respectively. This study provided further insight into the structure-function interaction of ScDAOCS with different penicillin substrates, thus providing a useful platform for further rational modification of its enzymatic properties.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18083859      PMCID: PMC2258576          DOI: 10.1128/AEM.02230-07

Source DB:  PubMed          Journal:  Appl Environ Microbiol        ISSN: 0099-2240            Impact factor:   4.792


  26 in total

1.  A comparison of three site-directed mutagenesis kits.

Authors:  P Loke; T S Sim
Journal:  Z Naturforsch C J Biosci       Date:  2001 Sep-Oct

2.  Mutation of N304 to leucine in Streptomyces clavuligerus deacetoxycephalosporin C synthase creates an enzyme with increased penicillin analogue conversion.

Authors:  H S Chin; J Sim; T S Sim
Journal:  Biochem Biophys Res Commun       Date:  2001-09-21       Impact factor: 3.575

3.  Engineering Streptomyces clavuligerus deacetoxycephalosporin C synthase for optimal ring expansion activity toward penicillin G.

Authors:  Chia-Li Wei; Yunn-Bor Yang; Wen-Ching Wang; Wen-Chi Liu; Jyh-Shing Hsu; Ying-Chieh Tsai
Journal:  Appl Environ Microbiol       Date:  2003-04       Impact factor: 4.792

4.  Performance of a recombinant strain of Streptomyces lividans for bioconversion of penicillin G to deacetoxycephalosporin G.

Authors:  Q Gao; J M Piret; J L Adrio; A L Demain
Journal:  J Ind Microbiol Biotechnol       Date:  2003-03-14       Impact factor: 3.346

5.  C-terminus modification of Streptomyces clavuligerus deacetoxycephalosporin C synthase improves catalysis with an expanded substrate specificity.

Authors:  H S Chin; T S Sim
Journal:  Biochem Biophys Res Commun       Date:  2002-07-05       Impact factor: 3.575

6.  A complete library of amino acid alterations at N304 in Streptomyces clavuligerus deacetoxycephalosporin C synthase elucidates the basis for enhanced penicillin analogue conversion.

Authors:  Hong Soon Chin; Kian Sim Goo; T S Sim
Journal:  Appl Environ Microbiol       Date:  2004-01       Impact factor: 4.792

Review 7.  Industrial production of beta-lactam antibiotics.

Authors:  R P Elander
Journal:  Appl Microbiol Biotechnol       Date:  2003-04-03       Impact factor: 4.813

8.  The role of arginine residues in substrate binding and catalysis by deacetoxycephalosporin C synthase.

Authors:  Sarah J Lipscomb; Hwei-Jen Lee; Mridul Mukherji; Jack E Baldwin; Christopher J Schofield; Matthew D Lloyd
Journal:  Eur J Biochem       Date:  2002-06

9.  Family shuffling of expandase genes to enhance substrate specificity for penicillin G.

Authors:  Jyh-Shing Hsu; Yunn-Bor Yang; Chan-Hui Deng; Chia-Li Wei; Shwu-Huey Liaw; Ying-Chieh Tsai
Journal:  Appl Environ Microbiol       Date:  2004-10       Impact factor: 4.792

10.  The structural basis of cephalosporin formation in a mononuclear ferrous enzyme.

Authors:  Karin Valegård; Anke C Terwisscha van Scheltinga; Alain Dubus; Graziella Ranghino; Linda M Oster; Janos Hajdu; Inger Andersson
Journal:  Nat Struct Mol Biol       Date:  2003-12-29       Impact factor: 15.369

View more
  4 in total

1.  Iterative combinatorial mutagenesis as an effective strategy for generation of deacetoxycephalosporin C synthase with improved activity toward penicillin G.

Authors:  Junjie Ji; Keqiang Fan; Xiuyun Tian; Xia Zhang; Yuxiu Zhang; Keqian Yang
Journal:  Appl Environ Microbiol       Date:  2012-08-24       Impact factor: 4.792

Review 2.  Directed evolution and rational approaches to improving Streptomyces clavuligerus deacetoxycephalosporin C synthase for cephalosporin production.

Authors:  Kian-Sim Goo; Chun-Song Chua; Tiow-Suan Sim
Journal:  J Ind Microbiol Biotechnol       Date:  2009-03-07       Impact factor: 3.346

Review 3.  Roles of 2-oxoglutarate oxygenases and isopenicillin N synthase in β-lactam biosynthesis.

Authors:  Patrick Rabe; Jos J A G Kamps; Christopher J Schofield; Christopher T Lohans
Journal:  Nat Prod Rep       Date:  2018-08-15       Impact factor: 13.423

4.  Mutation network-based understanding of pleiotropic and epistatic mutational behavior of Enterococcus faecalis FMN-dependent azoreductase.

Authors:  Jinyan Sun; Ohgew Kweon; Jinshan Jin; Gui-Xin He; Xiyu Li; Carl E Cerniglia; Huizhong Chen
Journal:  Biochem Biophys Rep       Date:  2017-11-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.